12:00 AM
 | 
Dec 17, 2012
 |  BioCentury  |  Emerging Company Profile

Alzinova: Freezing out AD

Alzinova Alzheimer's vaccine targets highly toxic oligomer form of beta amyloid

Alzinova AB is developing an Alzheimer's disease vaccine that uses an engineered beta amyloid mimic to raise an immune response against highly toxic AD-associated beta amyloid oligomers. The approach could yield a more potent protective immune response than prior vaccines aimed at larger fibrillar aggregates of beta amyloid.

Most therapeutic efforts in AD have focused on blocking the production or accumulation of beta amyloid, which over time leads to neurodegeneration and dementia.

The foremost strategy for blocking beta amyloid has been passive immunotherapy with mAbs that bind to amyloid plaques, the large fibrillar deposits of beta amyloid that are the neuropathological hallmarks of AD.

However, recent Phase III failures of the two most advanced mAbs - bapineuzumab from Pfizer Inc. and Johnson & Johnson and solanezumab from Eli Lilly and Co. - have raised questions about what form of beta amyloid is the best to target.

Alzinova thinks the oligomeric form of beta amyloid is a...

Read the full 787 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >